{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:58:04Z","timestamp":1786982284862,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007343","name":"Universit\u00e0 degli Studi di Brescia","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007343","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study aimed the role of volumetric and dissemination features of staging [18F]PSMA-1007 PET\/CT in predicting progression\u2010free survival (PFS) in patients with prostate cancer (PCa) and their relationship with the main clinical data (ISUP grade groups, number of lesions, PSA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We included 164 patients with high-risk PCa who underwent baseline [18F]PSMA-1007 PET\/CT. With the help of LIFEx version 7.7, the main volumetric and dissemination PET parameters were semi-automatically extracted: PSMA-prostate tumor volume (PSMA-TV), PSMA-prostate total lesion (PSMA-TL), PSMA total TV (PSMA-TTV), PSMA total TL (PSMA-TTL) and Dmax corrected for body-surface-area (Dmax\n                      <jats:sub>bsa<\/jats:sub>\n                      ). Spearman rank correlations between semiquantitative PET features and the clinical variables were analyzed. PFS estimates were plotted with the Kaplan\u2013Meier method.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A high correlation was seen between the number of lesions and both PSMA-TTL (r 0.725), and Dmaxbsa (r 0.935). A moderate correlation was registered between PSA and PSMA-TTV (r 0.333), PSMA-TTL (r 0.441), Dmax\n                      <jats:sub>bsa<\/jats:sub>\n                      (r 0.333), as well as between number of lesions and PSMA-TTV (r 0.342).\n                    <\/jats:p>\n                    <jats:p>\n                      After a median follow-up of 17\u00a0months (range 2\u201345), relapse\/progression happened in 17 patients (10%). PSA level, presence of distant metastases at staging, PSMA-TV, PSMA-TL, PSMA-TTL and Dmax\n                      <jats:sub>bsa<\/jats:sub>\n                      were significantly associated with PFS at univariate analysis, but only the presence of distant metastases, PSMA-TTL and Dmax\n                      <jats:sub>bsa<\/jats:sub>\n                      were confirmed to be independent prognostic factors.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Volumetric and dissemination features derived by staging [18F]PSMA-1007 PET\/CT were significantly correlated with PSA and number of lesions. The combination of PSMA-TTL and Dmax\n                      <jats:sub>bsa<\/jats:sub>\n                      was the best predictor of PFS and may help to better stratify PCa patients.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12149-025-02026-7","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T21:46:23Z","timestamp":1739828783000},"page":"518-526","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The prognostic role of staging [18F]PSMA-1007 PET\/CT volumetric and dissemination features in prostate cancer"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0810-6494","authenticated-orcid":false,"given":"Domenico","family":"Albano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Temponi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bertagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazareno","family":"Suardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Talin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco Lorenzo","family":"Bon\u00f9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Triggiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,17]]},"reference":[{"issue":"5","key":"2026_CR1","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1007\/s00259-021-05245-y","volume":"48","author":"F Ceci","year":"2021","unstructured":"Ceci F, Oprea-Lager DE, Emmett L, Adam JA, Bomanji J, Czernin J, et al. E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. Eur J Nucl Med Mol Imaging. 2021;48(5):1626\u201338. https:\/\/doi.org\/10.1007\/s00259-021-05245-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2026_CR2","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1053\/j.semnuclmed.2023.07.001","volume":"54","author":"MR Jochumsen","year":"2024","unstructured":"Jochumsen MR, Bouchelouche K. PSMA PET\/CT for primary staging of prostate cancer: an updated overview. Semin Nucl Med. 2024;54(1):39\u201345. https:\/\/doi.org\/10.1053\/j.semnuclmed.2023.07.001.","journal-title":"Semin Nucl Med"},{"issue":"1","key":"2026_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.euo.2021.12.002","volume":"6","author":"L Bianchi","year":"2023","unstructured":"Bianchi L, Castellucci P, Farolfi A, Droghetti M, Artigas C, Leite J, et al. Multicenter external validation of a nomogram for predicting positive prostate-specific membrane antigen\/positron emission tomography scan in patients with prostate cancer recurrence. Eur Urol Oncol. 2023;6(1):41\u20138. https:\/\/doi.org\/10.1016\/j.euo.2021.12.002.","journal-title":"Eur Urol Oncol"},{"issue":"10","key":"2026_CR4","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.2967\/jnumed.124.267751","volume":"65","author":"M Bauckneht","year":"2024","unstructured":"Bauckneht M, D\u2019Amico F, Albano D, Balma M, Cabrini C, Dondi F, et al. Composite prediction score to interpret bone focal uptake in hormone-sensitive prostate cancer patients imaged with [18F]PSMA-1007 PET\/CT. J Nucl Med. 2024;65(10):1577\u201383. https:\/\/doi.org\/10.2967\/jnumed.124.267751.","journal-title":"J Nucl Med"},{"issue":"12","key":"2026_CR5","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1007\/s00259-024-06797-5","volume":"51","author":"A Rizzo","year":"2024","unstructured":"Rizzo A, Morbelli S, Albano D, Fornarini G, Cioffi M, Laudicella R, et al. The Homunculus of unspecific bone uptakes associated with PSMA-targeted tracers: a systematic review-based definition. Eur J Nucl Med Mol Imaging. 2024;51(12):3753\u201364. https:\/\/doi.org\/10.1007\/s00259-024-06797-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"2026_CR6","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1007\/s00259-023-06456-1","volume":"51","author":"R Chen","year":"2024","unstructured":"Chen R, Ng YL, Yang X, Zhu Y, Li L, Zhao H, et al. Comparison of parametric imaging and SUV imaging with [68 Ga]Ga-PSMA-11 using dynamic total-body PET\/CT in prostate cancer. Eur J Nucl Med Mol Imaging. 2024;51(2):568\u201380. https:\/\/doi.org\/10.1007\/s00259-023-06456-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026_CR7","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.2967\/jnumed.118.224055","volume":"60","author":"A Gafita","year":"2019","unstructured":"Gafita A, Bieth M, Kr\u00f6nke M, Tetteh G, Navarro F, Wang H, et al. qPSMA: semiautomatic software for whole-body tumor burden assessment in prostate cancer using 68Ga- PSMA11 PET\/CT. J Nucl Med. 2019;60:1277\u201383.","journal-title":"J Nucl Med"},{"key":"2026_CR8","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1007\/s00259-020-04723-z","volume":"47","author":"J Ferdinandus","year":"2020","unstructured":"Ferdinandus J, Violet J, Sandhu S, Hicks R, Kumar AS, Iravani A, et al. Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617. Eur J Nucl Med Mol Imaging. 2020;47:2322\u20137.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026_CR9","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.2967\/jnumed.120.242057","volume":"61","author":"R Seifert","year":"2020","unstructured":"Seifert R, Herrmann K, Kleesiek J, Schafers M, Shah V, Xu Z, et al. Semiautomatically quantified tumor volume using (68)Ga-PSMA-11 PET as a biomarker for survival in patients with advanced prostate cancer. J Nucl Med. 2020;61:1786\u201392.","journal-title":"J Nucl Med"},{"issue":"9","key":"2026_CR10","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1097\/RLU.0000000000004763","volume":"48","author":"QA Shagera","year":"2023","unstructured":"Shagera QA, Karfis I, Sideris S, Guiot T, Woff E, Martinez-Chanza N, et al. Tumor volume on PSMA PET as a prognostic biomarker in prostate cancer patients treated with cabazitaxel. Clin Nucl Med. 2023;48(9):775\u201380. https:\/\/doi.org\/10.1097\/RLU.0000000000004763.","journal-title":"Clin Nucl Med"},{"issue":"8","key":"2026_CR11","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.2967\/jnumed.121.263006","volume":"63","author":"QA Shagera","year":"2022","unstructured":"Shagera QA, Artigas C, Karfis I, Critchi G, Chanza NM, Sideris S, et al. 68Ga-PSMA PET\/CT for response assessment and outcome prediction in metastatic prostate cancer patients treated with taxane-based chemotherapy. J Nucl Med. 2022;63(8):1191\u20138. https:\/\/doi.org\/10.2967\/jnumed.121.263006.","journal-title":"J Nucl Med"},{"issue":"11","key":"2026_CR12","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1007\/s12149-022-01785-x","volume":"36","author":"TA Telli","year":"2022","unstructured":"Telli TA, Ozguven S, Alan O, Filizoglu N, Ozturk MA, Sariyar N, et al. Role of baseline 68Ga-PSMA PET\/CT-derived whole-body volumetric parameters in predicting survival outcomes of metastatic castration-resistant prostate cancer patients receiving first-line treatment. Ann Nucl Med. 2022;36(11):964\u201375. https:\/\/doi.org\/10.1007\/s12149-022-01785-x.","journal-title":"Ann Nucl Med"},{"issue":"12","key":"2026_CR13","doi-asserted-by":"publisher","first-page":"4202","DOI":"10.1007\/s00261-020-02745-7","volume":"45","author":"Q Zou","year":"2020","unstructured":"Zou Q, Jiao J, Zou MH, Li MZ, Yang T, et al. Semi-automatic evaluation of baseline whole-body tumor burden as an imaging biomarker of 68Ga-PSMA-11 PET\/CT in newly diagnosed prostate cancer. Abdom Radiol (NY). 2020;45(12):4202\u201313. https:\/\/doi.org\/10.1007\/s00261-020-02745-7.","journal-title":"Abdom Radiol (NY)"},{"issue":"5","key":"2026_CR14","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1097\/MNM.0000000000001370","volume":"42","author":"A Aksu","year":"2021","unstructured":"Aksu A, Karahan \u015een NP, Tuna EB, Aslan G, \u00c7apa KG. Evaluation of 68Ga-PSMA PET\/CT with volumetric parameters for staging of prostate cancer patients. Nucl Med Commun. 2021;42(5):503\u20139. https:\/\/doi.org\/10.1097\/MNM.0000000000001370.","journal-title":"Nucl Med Commun"},{"issue":"9","key":"2026_CR15","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.3390\/cancers15092494","volume":"15","author":"D Albano","year":"2023","unstructured":"Albano D, Treglia G, Dondi F, Calabr\u00f2 A, Rizzo A, Annunziata S, et al. 18F-FDG PET\/CT maximum tumor dissemination (Dmax) in lymphoma: a new prognostic factor? Cancers (Basel). 2023;15(9):2494. https:\/\/doi.org\/10.3390\/cancers15092494.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"2026_CR16","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1007\/s12149-021-01705-5","volume":"36","author":"A Aksu","year":"2022","unstructured":"Aksu A, Vural Topuz \u00d6, Y\u0131lmaz G, \u00c7apa Kaya G, Y\u0131lmaz B. Dual time point imaging of staging PSMA PET\/CT quantification; spread and radiomic analyses. Ann Nucl Med. 2022;36(3):310\u20138. https:\/\/doi.org\/10.1007\/s12149-021-01705-5.","journal-title":"Ann Nucl Med"},{"issue":"4","key":"2026_CR17","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1097\/MNM.0000000000001539","volume":"43","author":"A Aksu","year":"2022","unstructured":"Aksu A, Vural Topuz \u00d6, Yilmaz B, Karahan \u015een NP, Acar E, \u00c7apa KG. Prediction of early biochemical response after 177Lu-PSMA radioligand therapy with 68Ga-PSMA PET, a different perspective with quantitative parameters. Nucl Med Commun. 2022;43(4):468\u201374. https:\/\/doi.org\/10.1097\/MNM.0000000000001539.","journal-title":"Nucl Med Commun"},{"issue":"16","key":"2026_CR18","doi-asserted-by":"publisher","first-page":"4786","DOI":"10.1158\/0008-5472.CAN-18-0125","volume":"78","author":"C Nioche","year":"2018","unstructured":"Nioche C, Orlhac F, Boughdad S, Reuz\u00e9 S, Goya-Outi J, Robert C, et al. LIFEx: a freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity. Cancer Res. 2018;78(16):4786\u20139. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-0125.","journal-title":"Cancer Res"},{"issue":"4","key":"2026_CR19","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.eururo.2017.10.027","volume":"73","author":"SP Rowe","year":"2018","unstructured":"Rowe SP, Pienta KJ, Pomper MG, Gorin MA. PSMA-RADS version 1.0: a step towards standardizing the interpretation and reporting of psma-targeted PET imaging studies. Eur Urol. 2018;73(4):485\u20137. https:\/\/doi.org\/10.1016\/j.eururo.2017.10.027.","journal-title":"Eur Urol"},{"issue":"8","key":"2026_CR20","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1007\/s12149-018-1274-8","volume":"32","author":"D Albano","year":"2018","unstructured":"Albano D, Bertoli M, Battistotti M, Rodella C, Statuto M, Giubbini R, et al. Prognostic role of pretreatment 18F-FDG PET\/CT in primary brain lymphoma. Ann Nucl Med. 2018;32(8):532\u201341. https:\/\/doi.org\/10.1007\/s12149-018-1274-8.","journal-title":"Ann Nucl Med"},{"issue":"1","key":"2026_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/hon.70009","volume":"43","author":"D Albano","year":"2025","unstructured":"Albano D, Bianchetti N, Talin A, Dondi F, Re A, Tucci A, et al. Prognostic role of pretreatment tumor burden and dissemination features from 2-[18F]FDG PET\/CT in advanced mantle cell lymphoma. Hematol Oncol. 2025;43(1): e70009. https:\/\/doi.org\/10.1002\/hon.70009.","journal-title":"Hematol Oncol"},{"key":"2026_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1515040","author":"D Albano","year":"2024","unstructured":"Albano D, Ravanelli M, Durmo R, Vesari A, Filice A, Rizzo A, et al. Semiquantitative 2-[18F]FDG PT\/CT-based parameters role in lymphoma. Front Med. 2024. https:\/\/doi.org\/10.3389\/fmed.2024.1515040.","journal-title":"Front Med"},{"issue":"12","key":"2026_CR23","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.2967\/jnumed.117.193581","volume":"58","author":"S Schmuck","year":"2017","unstructured":"Schmuck S, von Klot CA, Henkenberens C, Sohns JM, Christiansen H, Wester HJ, et al. Initial experience with volumetric 68Ga-PSMA I&T PET\/CT for assessment of whole-body tumor burden as a quantitative imaging biomarker in patients with prostate cancer. J Nucl Med. 2017;58(12):1962\u20138. https:\/\/doi.org\/10.2967\/jnumed.117.193581.","journal-title":"J Nucl Med"},{"issue":"5","key":"2026_CR24","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1007\/s12149-019-01342-z","volume":"33","author":"AET Brito","year":"2019","unstructured":"Brito AET, Mourato FA, de Oliveira RPM, Leal ALG, Filho PJA, de Filho JLL. Evaluation of whole-body tumor burden with 68Ga-PSMA PET\/CT in the biochemical recurrence of prostate cancer. Ann Nucl Med. 2019;33(5):344\u201350. https:\/\/doi.org\/10.1007\/s12149-019-01342-z.","journal-title":"Ann Nucl Med"},{"issue":"10","key":"2026_CR25","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1007\/s12149-019-01387-0","volume":"33","author":"C Schmidkonz","year":"2019","unstructured":"Schmidkonz C, Cordes M, Goetz TI, Prante O, Kuwert T, Ritt P, et al. 68Ga-PSMA-11 PET\/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients. Ann Nucl Med. 2019;33(10):766\u201375. https:\/\/doi.org\/10.1007\/s12149-019-01387-0.","journal-title":"Ann Nucl Med"},{"issue":"9","key":"2026_CR26","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1007\/s00259-021-05210-9","volume":"48","author":"IL Alberts","year":"2021","unstructured":"Alberts IL, Seide SE, Mingels C, Bohn KP, Shi K, Zacho HD, et al. Comparing the diagnostic performance of radiotracers in recurrent prostate cancer: a systematic review and network meta-analysis. Eur J Nucl Med Mol Imaging. 2021;48(9):2978\u201389. https:\/\/doi.org\/10.1007\/s00259-021-05210-9.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-025-02026-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-025-02026-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-025-02026-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T08:00:05Z","timestamp":1745308805000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-025-02026-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,17]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["2026"],"URL":"https:\/\/doi.org\/10.1007\/s12149-025-02026-7","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,17]]},"assertion":[{"value":"15 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}